Pay in 4 interest-free payments of $5.79 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
"These findings support a potential new therapeutic tool to effectively improve HbA1c levels well below 7% in such a challenging population of inadequately controlled basal insulin-treated type 2 diabetes with the benefit of substantial weight loss, no increase of hypoglycemia risk, and without having to increase insulin doses," said Julio Rosenstock, MD, lead author of the REIMAGINE 3 study. "As we look to provide more solid options for people with type 2 diabetes beyond insulin-based therapies, it's also important to note the safety and tolerability profile was consistent with previous GLP-1 RA trials." "Rather than focusing on glucose control alone, this strategy addresses weight, cardiovascular risk, and metabolic health together, with the goal of preventing long-term complications and, for some people, fundamentally resetting the trajectory of diabetes itself," said Vanita Aroda, MD, lead author of REIMAGINE 1. References American Diabetes Association
By providing detailed information about their product offerings, including the safety measures taken during production and the efficacy of the injections, manufacturers can instill confidence among global buyers
Learn why providers are concerned about the effects of popular weight loss drugs on fertility
According to the MHRA/EMC SmPC for Ozempic, nausea is very common (affecting 1/10 patients)
